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The mouse urokinase-type plasminogen activator (uPA) gene was used as a model macrophage colony-
stimulating factor 1 (CSF-1)-inducible gene to investigate CSF-1 signalling pathways. Nuclear run-on analysis
showed that induction of uPA mRNA by CSF-1 and phorbol myristate acetate (PMA) was at the transcriptional
level in bone marrow-derived macrophages. CSF-1 and PMA synergized strongly in the induction of uPA
mRNA, showing that at least some components of CSF-1 action are mediated independently of protein kinase
C. Promoter targets of CSF-1 signalling were investigated with NIH 3T3 cells expressing the human CSF-1
receptor (c-fms). uPA mRNA was induced in these cells by treatment with CSF-1, and a PEA3/AP-1 element at
22.4 kb in the uPA promoter was involved in this response. Ets transcription factors can act through PEA3
sequences, and the involvement of Ets factors in the induction of uPA was confirmed by use of a dominant
negative Ets-2 factor. Expression of the DNA binding domain of Ets-2 fused to the lacZ gene product prevented
CSF-1-mediated induction of uPA mRNA in NIH 3T3 cells expressing the CSF-1 receptor. Examination of ets-2
mRNA expression in macrophages showed that it was also induced synergistically by CSF-1 and PMA. In the
macrophage cell line RAW264, the uPA PEA3/AP-1 element mediated a response to both PMA and cotrans-
fected Ets-2. uPA promoter constructs were induced 60- to 130-fold by Ets-2 expression, and the recombinant
Ets-2 DNA binding domain was able to bind to the uPA PEA3/AP-1 element. This work is consistent with a
proposed pathway for CSF-1 signalling involving sequential activation of fms, ras, and Ets factors.
Macrophage colony-stimulating factor (CSF-1) acts primar-
ily on cells of the mononuclear phagocyte lineage to control
growth, differentiation, and survival of precursors as well as
functional modulation of mature macrophages (59). The cell
surface receptor for CSF-1 (CSF-1R) is a tyrosine kinase, the
product of the c-fms proto-oncogene (reviewed in references
59 and 68), first identified by its homology to the viral onco-
gene v-fms from the McDonough feline sarcoma virus (69).
Binding of CSF-1 is required for the kinase activity of the
normal CSF-1R, whereas the v-fms product is constitutively
active. The CSF-1R is most closely related to the platelet-
derived growth factor receptor and the c-kit gene product (59).
When CSF-1 binds to its receptor, a range of cellular pro-
teins and the receptor itself are phosphorylated (22). Like the
platelet-derived growth factor receptor, CSF-1R binds and ac-
tivates the 85-kDa subunit of phosphatidylinositol 39 kinase
(55), but the role of phosphatidylinositol 39 kinase in signal
transduction is not known. Other proteins which become ty-
rosine phosphorylated in response to CSF-1 include src family
kinases (17), tyrosine phosphatase PTP-1C (84), Shc proteins,
and an uncharacterized 150-kDa protein potentially involved
in the ras signalling pathway (43), although these may not all
be direct substrates of the receptor. The ras GTPase-activating
protein (GAP)-associated proteins p62 and p190, and to a
small extent GAP itself, have been reported to be phosphory-
lated in response to activated CSF-1R in fibroblasts (31, 55),
but this has not been observed with macrophages (55).
Some of the actions of CSF-1 are mimicked by the protein
kinase C (PKC) agonist phorbol myristate acetate (PMA) (75),
leading to speculation about the role of PKC in CSF-1 signal-
ling. Evidence for an increase in production of diacylglycerol
(an activator of PKC) after CSF-1 treatment of monocytes and
bone marrow-derived macrophages (BMM) (34, 76) and for an
increase in membrane-bound PKC activity (34, 66) has been
presented, but recent experiments fail to support these findings
(35). The generation of diacylglycerol is commonly the result
of activation of phospholipase C-g, an enzyme which cleaves
phosphatidylinositol-4,5-bisphosphate to diacylglycerol and in-
ositol-1,4,5-trisphosphate. Unlike the platelet-derived growth
factor receptor, CSF-1R does not activate phospholipase C-g
(21), and there is no associated increase in phosphatidylinosi-
tol turnover (34, 81). An alternative route for diacylglycerol
production may be by activation of a phosphatidylcholine-spe-
cific phospholipase C (83).
Evidence from a number of groups points to CSF-1-acti-
vated mitogenic signal pathways involving activation of fms,
ras, raf, Ets, and myc factors (7, 9, 39, 60). This may not be a
simple linear pathway, as recent experiments with a macro-
phage cell line showed that activation of Raf-1 was indepen-
dent of ras (10). The involvement of p21ras is well established
in experiments with fibroblasts. CSF-1 treatment of c-fms-ex-
pressing NIH 3T3 cells and BAC1.2F5 macrophages increased
the amount of active GTP-bound p21ras (10, 26, 31). Microin-
jection of anti-p21ras antibodies into v-fms-transformed fibro-
blasts caused reversion of the transformed phenotype (70), as
did overexpression of the catalytic domain of GAP (7) and
expression of a dominant negative Ets protein (39). Raf-1 was
activated by CSF-1 treatment, and expression of oncogenic
v-raf in a macrophage cell line led to CSF-1-independent
growth and constitutive expression of ets-2 and c-myc mRNAs
(9). Mutation of the CSF-1R at tyrosine 809, an autophosphor-
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ylation site, prevented the mitogenic response to CSF-1 and
impaired induction of c-myc, while induction of c-fos and junB
was unaffected (60, 64). The mitogenic response could be re-
stored by either c-myc (60), ets-2 (39), or ets-1 (61) expression.
Progress in defining promoter targets of CSF-1 action has
been made in studies of the long terminal repeat of NVL3, a
member of the VL30 family of mouse retrotransposons. A
ras-responsive promoter element which also mediated a re-
sponse to CSF-1 in NIH 3T3 fibroblasts expressing c-fms was
found (7). The sequence element is a compound PEA3/AP-1-
like site (54). Additional evidence for the role of p21ras in the
CSF-1 signalling pathway was obtained by showing that the
catalytic domain of GAP inhibited fms-mediated activation of
this element (7). Expression of a dominant negative Ets pro-
tein (Ets-2 DNA binding domain–LacZ fusion protein), which
presumably binds the PEA3 sequence, also prevented CSF-1
activation of this element (39). This work provided good evi-
dence for the roles of p21ras and Ets factors in both CSF-1-
mediated mitogenesis and induction of the NVL3 gene. More
recent data have implicated Ets factors in c-myc induction by
CSF-1 (61), in regulation of the CSF-1-responsive macrophage
scavenger receptor gene (82), and in CSF-1-mediated induc-
tion of the c-fos gene (33).
The ultimate aim of studies of growth factor-activated signal
transduction is to find all the molecular links from ligand
binding at the cell surface to transcription factor activation and
gene induction. Studies of nuclear targets of CSF-1 action in
macrophages have been hampered by a lack of well-character-
ized genes which are induced by CSF-1 in transfectable cell
lines, as primary macrophages and macrophage-like cell lines
are difficult to transfect efficiently (73). This paper addresses
the regulation of urokinase-type plasminogen activator (uPA),
which is acutely regulated by CSF-1 in mature macrophages.
uPA is a serine protease which cleaves the proenzyme plas-
minogen to plasmin, a protease of broad specificity (reviewed
in references 18 and 52). Plasmin directly catalyzes the degra-
dation of the extracellular matrix and also acts indirectly by
activating other proenzymes such as procollagenase. uPA ac-
tivity is associated with processes which require tissue remod-
elling or cell movement, such as wound healing and involution
of the mammary glands, and is frequently expressed at the
invading front of cancerous tissue. Since macrophage function
requires migration through tissues, uPA may be required to
allow the necessary extracellular matrix degradation. uPA ac-
tivity was first shown to be induced by CSF-1 in bone marrow-
derived macrophages (BMM) (42). Accumulation of uPA
mRNA in response to CSF-1 has been confirmed to occur in
BMM (30) and in the macrophage-like cell line RAW264 (72).
The level of macrophage or monocyte uPA mRNA has also
been found to be increased by PMA (30) and gamma inter-
feron (15) and decreased by dexamethasone and cyclic AMP
(cAMP) agonists such as cholera toxin (15).
In this work we have examined the regulation of the uPA
gene by CSF-1 and PMA. These agents synergistically induced
uPA mRNA in macrophages, suggesting divergent pathways of
activation. The difficulty of transfecting primary macrophages
has meant that other cell types have had to be used for tran-
sient-transfection analysis. A PEA3/AP-1-like element at
22430 of the mouse uPA promoter was shown to be important
in the induction of the gene by PMA in RAW264 cells and by
CSF-1 in NIH 3T3 cells expressing c-fms. This element was first
described by Rørth et al. (56) as being required for induction
of uPA transcription by PMA and epidermal growth factor in
keratinocytes. The element is conserved in mouse, pig, and
human promoters (12) and is required for induction by PMA
in a pig kidney epithelial cell line (41) and by PMA and basic
fibroblast growth factor in NIH 3T3 cells (5). Hence, diverse
signalling pathways can converge on this one element. Here we
provide evidence that Ets-2 can bind and activate transcription
through this element.
MATERIALS AND METHODS
Materials. Recombinant human CSF-1 was kindly provided by Chiron Corp.
PMA was obtained from Sigma.
Cell culture. BALB/c BMM were differentiated in culture with CSF-1 as
previously described (73). The RAW264 macrophage-like cell line (53) is derived
from tumor cells of an Abelson leukemia virus-infected mouse. This cell line was
routinely grown in bacteriological petri dishes in RPMI 1640 medium with 5%
fetal calf serum. NIH 3T3 fibroblasts, NIH 3T3 cells expressing human c-fms
(63), and NIH 3T3 cells expressing both c-fms and the human Ets-2 DNA binding
region fused to lacZ (39) were cultured in Dulbecco modified Eagle medium
supplemented with 10% fetal calf serum.
Northern (RNA) analysis. Total RNA was extracted from cells by the method
of Chomczynski and Sacchi (13). Total RNA (10 mg) was run on MOPS (mor-
pholinepropanesulfonic acid)-formaldehyde denaturing gels, transferred to Hy-
bond N nylon membranes, and hybridized with 32P-labelled DNA probes. The
probes used were mouse uPA, a 1.2-kb PstI cDNA fragment (4); mouse Ets-2,
excised from the plasmid Ets.pECE (obtained from R. Maki, La Jolla Cancer
Research Foundation); 18S rRNA, a 24-bp oligonucleotide complementary to
murine 18S rRNA (59CAT GGT AGG CAC GGC GAC TAC CAT39); and
human K-rev-1 (rap 1A), a gene fragment obtained by PCR.
Nuclear run-on analysis. The plasmids used were pGEM2 (Promega) (as a
control); uPA 59, a genomic fragment of mouse uPA from18 to1398 (including
exon 1, intron 1, and the beginning of exon 2) in pBluescript; uPA39, a fragment
encompassing bp 424 to 1643 of the 2.3-kb mouse uPA cDNA in pGEM2;
b-actin, a 1.8-kb chicken b-actin cDNA fragment in pGEM2; c-fms, p755 con-
taining the 3.7-kb mouse c-fms cDNA, obtained from L. Rohrschneider (Fred
Hutchinson Cancer Research Center, Seattle, Wash.); lysozyme, pMLC which
contains a 780-bp fragment of mouse lysozyme M cDNA, obtained from R.
Renkawitz (Max Planck Institute, Munich, Germany).
Plasmids were linearized, phenol-chloroform extracted, ethanol precipitated,
and resuspended in 10 mM Tris-HCl (pH 8)–1 mM EDTA. The plasmid (1 mg)
was slot blotted onto Hybond N membranes. Cells (2 3 107 to 3 3 107 per
treatment group) were harvested and rinsed twice with ice-cold phosphate-
buffered saline (PBS). The cells were lysed with 5 ml of ice-cold lysis buffer (10
mM Tris HCl [pH 7.4], 10 mMNaCl, 3 mMMgCl2, 0.5% Nonidet P-40), pelleted
(500 3 g, 5 min), and then resuspended in 1 ml of lysis buffer. Nuclei were
pelleted (5003 g, 5 min) and resuspended in 100 ml of glycerol storage buffer (50
mM Tris HCl [pH 8.3], 40% glycerol, 5 mM MgCl2) with 40 U of RNasin
(Boehringer Mannheim). To 100 ml of nuclei were added 100 ml of reaction
buffer (10 mM Tris HCl [pH 8.0], 5 mM MgCl2, 0.3 M KCl, 1 mM ATP, 1 mM
CTP, 1 mM GTP, 5 mM dithiothreitol) and 50 mCi of [a-32P]UTP (3,000
Ci/mmol; Amersham). Nuclei were incubated at 308C for 30 min with shaking.
RNA was then extracted by the method of Chomczynski and Sacchi (13) with the
addition of 20 mg of carrier yeast tRNA (Boehringer Mannheim).
Filters were prehybridized and hybridized in 53 SSPE (13 SSPE is 0.18 M
NaCl, 10 mM NaH2PO4, and 1 mM EDTA [pH 7.7]), 53 Denhardt’s solution,
0.5% sodium dodecyl sulfate (SDS), 50 mg of denatured herring sperm DNA per
ml, and 200 mg of yeast tRNA per ml at 428C in small glass scintillation vials
inside rolling hybridization bottles. The prehybridization solution was removed
after at least 6 h of incubation, and equivalent counts of RNA from each sample
in 0.5 ml of hybridization solution were added. Hybridization proceeded for 36
h. The filters were washed twice for 20 min each time with 23 SSC (13 SSC is
0.15 M NaCl plus 0.015 M sodium citrate) at 428C, twice for 20 min each time
with 13 SSC–0.1% SDS at 558C, and once for 30 min with 23 SSC with 10 mg
of RNase A at 378C and finally were rinsed several times in 23 SSC. The filters
were exposed for 2 days to 2 weeks.
Transfection analysis. RAW264 cells were transfected by electroporation with
10 mg of plasmid DNA as described previously (73). We found that the voltage
needed to be optimized for the individual electroporator in use, as delivered
voltages differed from the readout values. puPACAT2 plasmids containing the
mouse uPA promoter linked to the chloramphenicol acetyltransferase (CAT)
gene (see Fig. 3E) have been described (12). Plasmid pPR99, constructed by
Rørth et al. (56), contains a 90-bp HaeIII fragment of the mouse uPA promoter
(22446 to22356) linked to the uPA proximal promoter (2114 to1398) and the
Escherichia coli CAT gene. The related plasmids pPR119 and pPR127 contain
point mutations in the PEA3/AP-1 site of the HaeIII fragment (56) (see Fig. 3E).
pPR126 contains only the proximal promoter (2114 to1398) and the CAT gene.
Plasmid pGLuPA-6.6 contains the same promoter region (26616 to 1398) as
puPACAT2, inserted into the HindIII site of the luciferase reporter plasmid
pGL2-Basic (Promega). Plasmid pGL99 is equivalent to pPR99 but drives the
luciferase reporter gene. The mouse Ets-2 expression vector Ets.pECE and PU.1
expression vector PU.pECE were obtained from R. Maki (La Jolla Cancer
Research Foundation). Mouse Elf-1 expression vector was obtained from Mar-
tine Roussel (St. Jude Children’s Research Hospital, Memphis, Tenn.). Mouse
PEA3 cDNA (a gift from J. Hassell, McMaster University, Hamilton, Ontario,
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Canada) was inserted into a cytomegalovirus promoter-driven expression plas-
mid. The expression vector pECE (23) was used as a control in cotransfection
experiments. CAT assays were performed as described previously (12), and
luciferase assays were performed as described in Promega protocols. Total pro-
tein was assayed with a Bio-Rad Bradford assay kit.
NIH 3T3 fibroblasts were transfected by calcium phosphate coprecipitation
and assayed for secreted human placental alkaline phosphatase as described
previously (49). The v-fms expression plasmid pSMFeSV (62) was used in co-
transfections.
Electrophoretic mobility shift analysis (EMSA). Extracts were prepared from
approximately 3 3 107 BMM nuclei by a modification of the method of Osborn
et al. (48). Cells were harvested, washed with PBS, and resuspended in 5 ml of
hypotonic wash buffer (HWB) (10 mM HEPES [N-2-hydroxyethylpiperazine-N9-
2-ethanesulfonic acid] [pH 7.9], 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA
[ethylene glycol-bis(b-aminoethyl ether)-N,N,N9-N9-tetraacetic acid]). After the
extracts were pelleted and resuspended in 0.5 ml of HWB, 1 ml of HWB
containing 0.05% Nonidet P-40 was added. Nuclei were spun down (500 3 g, 5
min, 48C; Heraeus Biofuge) and resuspended in 50 to 100 ml of nuclear extrac-
tion buffer (20 mMHEPES [pH 7.9], 0.42 M NaCl, 20% glycerol, 0.2 mM EDTA,
0.2 mM EGTA) and left on ice for 10 min. Nuclei were spun down (15,000 3 g,
10 min, 48C; Heraeus Biofuge) and the supernatant was removed and stored at
2208C. All solutions were ice cold and contained 1 mM phenylmethylsulfonyl
fluoride, 1 mM dithiothreitol, 10 mg of leupeptin per ml, and 10 mg of aprotinin
per ml. Protein extract (1 to 5 mg in 2 ml of nuclear extraction buffer) was
incubated with 0.027 pmol of end-labelled double-stranded oligonucleotide
probe in a total volume of 10 ml containing 20 mM HEPES (pH 7.9), 0.5 mM
dithiothreitol, 12% glycerol, 50 mM NaCl, 0.5 mg of poly[d(I-C)], and 1 mM
EDTA. After the addition of protein, samples were incubated at room temper-
ature for 30 min and run on 5 to 6% acrylamide gels (acrylamide-to-bis ratio,
29:1) at 100 V in 0.53 Tris-borate-EDTA buffer. The gels were dried and
visualized by autoradiography.
Mouse Ets-2 DNA binding domain (amino acids 334 to 466) was expressed in
E. coli as a glutathione S-transferase (GST) fusion protein with the vector
pGEX2T (Pharmacia). Protein was purified with glutathione-agarose (Sigma),
and 10 ng of protein was used in EMSA as described above, with the omission of
poly[d(I-C)] from the binding reaction. Expressed and purified GST protein was
used as a control.
RESULTS
Northern analysis of uPA in macrophages. The effects of
CSF-1 and PMA on uPA mRNA levels were examined with
BMM and the CSF-1-independent macrophage-like cell line
RAW264 (Fig. 1). Cells were plated overnight either with or
without CSF-1 and then either harvested or treated for a fur-
ther 4 h with PMA. The level of uPA mRNA was approxi-
mately 40-fold higher in CSF-1-treated BMM than in CSF-1-
starved cells. The decline in uPA mRNA level with overnight
CSF-1 starvation is fully reversible with the readdition of
CSF-1 (71), so the decrease in mRNA level is not due to cell
death. RAW264 cells also responded to CSF-1, giving an in-
duced level of uPA mRNA that was approximately 25% of that
in CSF-1-treated BMM. In six experiments, RAW264 cells
responded to CSF-1 with three- to sixfold inductions of uPA
mRNA during 8- to 24-h incubations (71, 72). In experiments
examining the time course of induction of uPA mRNA by
CSF-1 in both BMM and RAW264 cells, mRNA levels were
increased after 1 to 2 h, reached a maximum at 8 to 16 h, and
remained elevated above basal levels thereafter, provided that
CSF-1 concentrations remained saturating (25, 30, 72).
The tumor-promoting phorbol ester PMA is believed to
exert most of its effects by activation of PKC. PMA alone had
a moderate effect on uPA levels in BMM but gave a very large
increase in uPA levels in RAW264 cells (Fig. 1). It has been
suggested that similarities in the actions of CSF-1 and PMA in
macrophages are due to a common activation of PKC (75). If
PMA and CSF-1 both induce uPA by activation of PKC, then
treatment with optimal concentrations of the two agents to-
gether should not have an additive effect. Adding PMA to
CSF-1-pretreated BMM increased uPA mRNA levels 400-fold
above the level for CSF-1-starved cells (Fig. 1). Since CSF-1
and PMA added alone gave 40- and 20-fold inductions, respec-
tively, this effect is much greater than additive. The synergism
of the two factors added at saturating concentrations indicates
that CSF-1 does not induce uPA by merely activating PKC in
a manner similar to that of PMA. Although CSF-1 and PMA
may activate some of the same pathways, they do so in distinct
manners such that synergy is possible. In RAW264 cells the
effect of CSF-1 and PMA together was also more than additive.
The effect was less striking than in BMM because of the large
level of induction by PMA alone.
Ets family transcription factors are implicated in CSF-1 in-
duction of the NVL3 and c-myc genes and in mitogenesis in
fibroblasts (39, 61). Ets factors are a family defined by homol-
ogy to the v-Ets oncogene product of E26 erythroblastosis virus
and include the products of the ets-1, ets-2, erg, fli-1, spi-1
(PU.1), elf-1, and PEA3 genes (78). PU.1 is a macrophage- and
B-cell-specific transcription factor (57), but PU.1 expression
and interaction with its target sequence are not affected by
CSF-1 (58). Ets-2 protein and mRNA were found to be in-
duced in chicken BMM by the chicken myelomonocytic growth
factor and PKC activators (8). In the mouse macrophage cell
line BAC1.2F5, ets-2 mRNA was induced by CSF-1 (9). Ex-
amination of ets-2 mRNA expression in macrophages showed
induction by PMA and CSF-1 closely paralleling that of uPA
mRNA, with apparent synergism between the two stimuli (Fig.
1). A time course of the response to CSF-1 in BMM showed a
peak of ets-2 mRNA expression at 1 to 2 h, preceding the major
induction of uPA (25). In RAW264 cells, the response of ets-2
mRNA to CSF-1 was barely detectable even at 2 h (25), al-
though the message was induced by PMA (Fig. 1). The possi-
bility that transcription factor Ets-2 can regulate uPA expres-
sion is addressed later in this paper. If induction of Ets-2 is a
prerequisite for uPA induction, then it would be anticipated
that blockage of protein synthesis would prevent uPA induc-
tion. Investigations of such events are difficult, as both ets-2
mRNA and uPA mRNA are induced in macrophages by cy-
cloheximide (14, 25).
Effects of PMA and CSF-1 on rates of transcription.Nuclear
run-on analyses were performed to establish whether the in-
creases in mRNA levels observed with PMA and CSF-1 were
due to transcriptional activation. Figure 2A shows results of an
analysis of the rates of transcription of a number of genes in
BMM treated with CSF-1 and PMA. Two mouse uPA clones
FIG. 1. Northern analysis of uPA and ets-2 mRNA expression in RAW264
cells and BMM. RAW264 cells and 6-day-old BMM were plated overnight (16 h)
with or without 104 U of CSF-1 per ml. Cells were then either harvested or
treated for a further 4 h with 200 ng of PMA per ml. Cell treatments were as
follows: control, 16 h without CSF-1; 1CSF-1, 16 h with CSF-1; 1PMA, PMA
added to medium for 4 h after incubation without CSF-1 for 16 h; and 1CSF-1
1PMA, PMA added to medium for 4 h after incubation with CSF-1 for 16 h.
Total RNA was extracted and hybridized with cDNA probes for uPA and Ets-2.
An oligonucleotide probe for 18S rRNA is shown as a control for loading.
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were used. uPA 59 is a genomic clone containing the noncoding
first exon, the first intron, and the beginning of exon 2. uPA 39
is a cDNA clone containing bp 424 to 1643 (exons 5 to 11) of
the 2.3-kb uPA mRNA (4, 20). These two clones were used in
order to distinguish between effects on initiation of transcrip-
tion and effects on elongation. Earlier results have shown tran-
scriptional termination or pausing in the second intron of the
uPA gene in both fibroblasts and thioglycolate-elicited perito-
neal macrophages (3). The results here do not suggest that
release of a transcriptional blockage is a major form of regu-
lation of the uPA gene in BMM or RAW264 cells. Both CSF-1
and PMA gave a clear increase in the rate of transcription of
uPA in BMM (Fig. 2A). In RAW264 cells, PMA treatment
increased the rate of transcription, but there was no detectable
change when cells were treated with CSF-1 for either 4 or 12 h
(Fig. 2B). This suggests that the moderate level of induction of
uPA mRNA by CSF-1 in RAW264 cells (Fig. 1) occurs at a
posttranscriptional level.
The rates of uPA transcription in BMM and RAW264 cells
were compared by using equivalent counts per minute of
run-on transcripts from the two cell types (Fig. 2B). Such an
approach assumes that the total nascent transcripts produced
per cell per unit of time is independent of the cell type. This is
unlikely to be the case, as RAW264 cells proliferate more
rapidly than BMM. However, even if it is assumed that
RAW264 nuclei incorporated twice as much radiolabel as
BMM nuclei, the rate of transcription of uPA in BMM treated
with CSF-1 was still apparently much greater than in RAW264
cells with or without CSF-1 (Fig. 2B). The results of Northern
and nuclear run-on analyses suggest that the CSF-1 respon-
siveness of the uPA gene is impaired in RAW264 cells com-
pared with that in BMM. CSF-1 and PMA treatments also
affected the transcription of other genes studied. In both
RAW264 cells and BMM, transcription of c-fms and the ly-
sozyme gene, which are macrophage marker genes, was re-
duced by CSF-1 and PMA. Both of these agonists are known to
down-regulate c-fms mRNA in these cells (85).
Promoter studies in RAW264 cells. In previous work, we
showed that RAW264 cells could be effectively transfected by
electroporation but that BMM could not be transfected by the
same method because of DNA-dependent cell death (73). Un-
fortunately no macrophage cell line which is readily transfect-
able and gives a good transcriptional response to CSF-1 has yet
been identified. Previously reported analysis of the mouse uPA
promoter in RAW264 cells (12) showed that maximal expres-
sion required the first intron and 6.6 kb of promoter sequence.
The full-length (6.6-kb) uPA promoter was induced sixfold by
PMA, but no induction was seen with CSF-1 (72). Basal ex-
pression of the pig promoter transfected into RAW264 cells
was dependent on the PEA3/AP-1 element first described by
Rørth et al. (12, 56).
Rørth et al. (56) prepared plasmid pPR99 containing a
90-bpHaeIII fragment with the PEA3/AP-1 element (22446 to
22356) linked to the uPA-proximal promoter region (2114 to
1398) and the CAT reporter gene (Fig. 3E). The activity of
this construct in RAW264 cells was compared with that of the
full-length promoter in puPACAT2 (26.6 kb to 1398) and
that of the promoter truncated to 22657. Truncation of the
promoter to 22657 reduced the basal level of expression (12)
but gave little change in PMA inducibility (Fig. 3A). Thus,
regions upstream of 22657 have enhancer activity (12) but are
not required for the PMA response. The PMA-induced level of
expression from pPR99 is seven to eight times that of the
full-length promoter in puPACAT2. The higher level of induc-
ibility may be due to the deletion of inhibitory regions, such as
those found in the human promoter between 2660 and 2338
(11) and between 21824 and 21572 (77), both of which are 39
to the PEA3/AP-1 element.
Mutating either the PEA3 half (plasmid pPR119) or the
AP-1 half (plasmid pPR127) (56) of the PEA3/AP-1 site
greatly reduced the PMA response (Fig. 3B). As the basal level
of expression from these plasmids was very close to the exper-
imental background level, it was not possible to accurately
determine the fold induction by PMA. Using analogous con-
structs in a luciferase vector in which low-level activity is more
easily detectable, we showed that the PEA3 and AP-1 muta-
tions caused only a 50% drop in activity (25). Hence, the
reductions in PMA-induced activity in pPR119 and pPR127
are not likely to be due to a drop in basal expression. The
PEA3/AP-1 element can mediate a response to PMA in
RAW264 cells, and both halves of the site are required for
maximal induction. A plasmid with only the uPA-proximal
promoter (2114 to 1398), pPR126, was not PMA responsive
(Fig. 3B).
Figure 1 shows that the expression of ets-2 mRNA closely
paralleled that of uPA. The ets-2 and uPA genes may be reg-
ulated together through common pathways, or Ets-2 levels may
control uPA mRNA levels. Since the peak of ets-2 mRNA
expression precedes most of the uPA mRNA induction (25)
and PEA3 sequences are bound by Ets family transcription
factors (79), the second possibility is an attractive hypothesis.
The relatively impaired response of RAW264 cells to CSF-1
may be a consequence of the failure to induce Ets-2. For this
reason, the effect of Ets-2 expression on promoter activity in
FIG. 2. Nuclear run-on analysis of transcription of the uPA, b-actin, c-fms,
and lysozyme genes in BMM and RAW264 cells. uPA59 is a genomic fragment
of uPA including exon 1 and intron 1. uPA39 is a cDNA clone encompassing bp
424 to 1643 of the 2.3-kb mouse uPA cDNA. pGEM2 plasmid DNA was used as
a control. (A) Six-day-old BMM were starved of CSF-1 for 15 h (control), grown
in the continued presence of CSF-1 (1CSF-1), or starved of CSF-1 for 15 h prior
to the addition of PMA for 1 h (1PMA) before the isolation of nuclei. (B)
RAW264 cells were grown without additions (control), with CSF-1 for 12 h
(1CSF-1 12 hr), with CSF-1 for 4 h (1CSF-1 4 hr), or with PMA for 1 h
(1PMA). Seven-day-old BMM grown in the continued presence of CSF-1
(1CSF-1) were assayed in the same experiment. These assays were performed
with duplicate cell samples, and results are representative of two independent
run-on analyses. CSF-1 was used at 104 U/ml, and PMA was used at 200 ng/ml.
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RAW264 cells was examined. Figure 3C shows the results of
the cotransfection of an Ets-2 expression plasmid (Ets.pECE)
with pPR99 and mutated constructs into RAW264 cells. Ets-2
expression dramatically increased the activity of the uPA pro-
moter in pPR99. Mutations of the PEA3 site (pPR119) and the
AP-1 site (pPR127) both reduced the response to cotrans-
fected Ets-2. It is likely that Ets-2 activates transcription di-
rectly through the PEA3/AP-1 site, but the possibility that
Ets-2 induces another factor involved in transactivation cannot
be ruled out. The fact that the AP-1 mutation decreases the
FIG. 3. (A) PMA response of uPA promoter constructs in transiently transfected RAW264 cells. The cells were electroporated with 10 mg of puPACAT2 and molar
equivalent amounts of puPACAT2-2657 and pPR99. The cells were divided into two groups for treatment with or without 200 ng of PMA per ml at 24 h after
transfection. The cells were harvested after a further 24 h in culture. CAT activity was normalized to that of puPACAT2 without PMA treatment. (B) Involvement of
the PEA3/AP-1 site in the PMA response. RAW264 cells were electroporated with 10 mg of uPA promoter construct, and the cells were divided into two groups for
treatment with or without 100 ng of PMA per ml at 24 h after transfection. The cells were harvested after a further 24 h in culture. CAT activity was normalized to
the results for pPR99 treated with PMA. Results shown are the averages from four separate experiments (error bars show standard deviations). Plasmid constructs are
shown in Fig. 3E. pPR126 contains only the uPA proximal promoter region (2114 to 1398) linked to the CAT gene (56). (C) Involvement of the PEA3/AP-1 site in
the response to Ets-2 expression. RAW264 cells were electroporated with 10 mg of uPA promoter construct and 1 mg of either an Ets-2 expression plasmid (Ets.pECE)
or control expression vector (pECE). Cells were harvested 48 h after transfection. CAT activity was normalized to results for pPR99 with cotransfected Ets.pECE.
Results shown are the averages from four separate experiments (error bars show standard deviations). (D) Transactivation of the uPA promoter by various Ets family
members. RAW264 cells were electroporated with 10 mg of pGLuPA-6.6 or a molar equivalent amount of pGL99 together with 2 mg of Ets family expression plasmids
or a control plasmid, pECE. Cells were harvested 24 h after transfection. Results were normalized to those for cotransfection of each of the reporter plasmids with
pECE. Absolute values obtained for pGL99 were approximately 25% of those for pGLuPA-6.6. Results from three separate experiments (averages of duplicates) are
indicated by the solid, hatched, and shaded bars. (E) Diagram of uPA promoter constructs used in transfection experiments. The uPA exonic sequences included in
constructs are noncoding sequences (20). Derivatives of plasmid pPR99 contained the mutations shown in the PEA3/AP-1 site (56).
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response to Ets-2 emphasizes the compound nature of this
element; both halves of the element are required for full en-
hancer activity. The uPA proximal promoter region alone in
pPR126 did not respond to Ets-2. The residual Ets-2 response
seen with the PEA3/AP-1 mutant constructs pPR119 and
pPR127 may be due to another region within the 90-bp HaeIII
fragment which has a potential Ets factor binding sequence
(GGAT at22396 bp in the mouse promoter). This sequence is
not perfectly conserved among mouse, pig, and human pro-
moters (12), and whether it has an enhancer function has not
been established.
Transactivation of the uPA promoter is not a property of all
Ets factors. Figure 3D shows results of cotransfection of uPA
promoter constructs with expression vectors for the Ets family
members Ets-2, Elf-1, PU.1, and PEA3. The promoter con-
structs used were pGLuPA-6.6, which contains the same pro-
moter region as puPACAT2 (26616 to 1398) linked to the
luciferase reporter gene, and pGL99, which is a luciferase
version of pPR99 (Fig. 3E). For both plasmids, the induction
by Ets-2 was 60- to 130-fold. It should be noted that the level
of luciferase activity from pGL99 was approximately 25% of
that from pGLuPA-6.6. Expression of PU.1 and Elf-1 had little
or no effect on promoter activity, and PEA3 gave only a mod-
est increase compared with that of Ets-2. Although native PU.1
is expressed relatively highly in RAW264 cells (57), we still
observe some transactivation by coexpressed PU.1 on several
other promoters. Our previous work showed that PU.1 from
RAW264 nuclear extracts did not bind the uPA PEA3/AP-1
element under EMSA conditions (12). An Ets-1 expression
vector gave the same magnitude of response as Ets-2 (result
not shown). Ets-1 is not a good candidate for regulating ex-
pression in macrophages, as it is expressed strongly in lym-
phoid cells but not in macrophage or myeloid cell lines (37).
Consistent with the results of nuclear run-on (Fig. 2), which
show little effect of CSF-1 on uPA gene transcription in
RAW264 cells, no activation of the uPA promoter by CSF-1
was detected in transfection analyses with this cell line (72).
Stably integrated full-length (6.6-kb) promoter was also not
responsive to CSF-1 (25). Results of transient and stable trans-
fection therefore support the idea that the three- to sixfold
induction of uPA mRNA in RAW264 cells over an 8- to 16-h
treatment with CSF-1 (Fig. 1) (71, 72) is largely a posttran-
scriptional effect.
Regulation of the uPA gene by CSF-1 in NIH 3T3 cells. As
transcriptional regulation of uPA by CSF-1 in RAW264 cells
could not be demonstrated, the regulation of uPA was exam-
ined with a heterologous system, i.e., with NIH 3T3 fibroblasts
expressing the human CSF-1R, c-fms (referred to herein as
NIH 3T3/c-fms). The kinetics of stimulation of uPA mRNA
expression by the addition of recombinant human CSF-1 to
NIH 3T3/c-fms are depicted in Fig. 4. The level of uPA mRNA
was rapidly stimulated by CSF-1 in these cells, increasing by
eightfold within 1 h. The level thereafter declined but at 2 and
4 h remained threefold higher than in unstimulated cells. This
level of expression was maintained even after 24 h of CSF-1
stimulation (16). The kinetics of induction are in contrast to
the results found for CSF-1 stimulation of uPA mRNA in
BMM (71) or RAW264 cells (72), in which expression peaks at
8 to 16 h. Similarly, the NVL3 retrotransposon in NIH 3T3/c-
fms is maximally induced 16 to 24 h after CSF-1 stimulation
(7).
To examine the role of Ets proteins in the induction of uPA,
we next examined the effect of a dominant negative repressor
of Ets action. Stable expression of the DNA binding domain of
human Ets-2 fused to the lacZ gene product (39) with c-fms in
NIH 3T3 cells prevented CSF-1 induction of uPA mRNA (Fig.
4). This is similar to the result obtained for CSF-1 stimulation
of NVL3 expression in NIH 3T3/c-fms. The NVL3 gene con-
tains a PEA3/AP-1-like element which behaves as both a ras-
responsive element and a CSF-1-responsive element (7). The
possibility that the uPA PEA3/AP-1 element can behave as a
CSF-1-responsive element was addressed by transient transfec-
tions into NIH 3T3 cells.
uPA promoter activity in NIH 3T3/c-fms. Promoter elements
involved in the CSF-1 response of NIH 3T3/c-fms were ana-
lyzed by transient transfection. Plasmid pPR99 and the mutant
plasmids pPR119 and pPR127 (56) were transfected into NIH
3T3 cells with and without cotransfected v-fms expression plas-
mid, which encodes a constitutively active form of the CSF-1R
(62) (Fig. 5A). The basal level of activity of pPR99 was low in
NIH 3T3 cells, but v-fms expression activated this reporter by
an average of 25-fold in three separate experiments. In con-
trast, the activities of reporters that contained point mutations
in either the PEA3 site (pPR119) or the AP-1 site (pPR127)
were not greatly stimulated by v-fms. In a second set of exper-
iments, reporters were transfected into NIH 3T3/c-fms cells
and stimulation by CSF-1 was determined (Fig. 5B). In these
experiments, pPR99 activity was stimulated three- to fourfold,
while the activities of pPR119 and pPR127 were not signifi-
cantly affected by the ligand-activated CSF-1R. The CSF-1-
mediated increase in uPA mRNA (Fig. 4) is therefore likely to
involve activation of the PEA3/AP-1 element and requires Ets
family transcription factors.
Proteins binding the PEA3/AP-1 element. The transient-
transfection analyses described above implicate AP-1 or cAMP
response element (CRE)-binding and Ets family transcription
factors in the action of CSF-1 and PMA. EMSA was per-
formed in order to determine whether AP-1 transcription fac-
tors are able to bind the octameric AP-1 site of the uPA
element and whether any proteins binding the PEA3 site are
detectable.
In EMSA the uPA PEA3/AP-1 element (uPA wt oligonu-
cleotide) formed two major complexes with nuclear proteins
from CSF-1-treated BMM (Fig. 6A). These complexes were
abolished by mutation of the AP-1 half of the element (uPA
FIG. 4. Effects of CSF-1 and Ets-2 DNA binding domain on uPA mRNA
expression in NIH 3T3 cells. NIH 3T3 cells were stably transfected with a
construct expressing Ets-2 DNA binding domain fused to the lacZ gene (pAPr-
etsZ-neo) and a retroviral vector expressing the CSF-1R (39). Control cells were
transfected with the parental expression vector (39) and the CSF-1 expression
vector. RNA was prepared from NIH 3T3 cells expressing human c-fms (open
circles) and NIH 3T3 cells expressing both c-fms and the human Ets-2 DNA
binding domain fused to the lacZ gene product (solid circles). The cells were
serum starved for 24 h and then treated with 5 3 104 U of CSF-1 per ml for the
indicated times (in hours). Northern blot analysis was performed with a uPA-
specific probe and a K-rev-specific probe to control for RNA loading. The data
shown are the uPA hybridization/K-rev-1 hybridization ratios as determined by
scanning of autoradiographs with a model SL-504-XL laser scanning densitom-
eter (Biomed Instruments).
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M5). Mutation of the PEA3 site (uPA M7) or use of a trun-
cated oligonucleotide completely lacking the PEA3 site (uPA
CRE) did not affect the formation of these complexes. Thus,
the major proteins detectable under the conditions used bind
only to the AP-1 half of the element. The possibility that
phosphorylation may be necessary for factor binding to the
PEA3 half was considered, but inclusion of phosphatase inhib-
itors in extraction and binding buffers did not alter the pattern
of binding (25).
Incubation of CSF-1-treated BMM nuclear extract with an
oligonucleotide able to bind AP-1 yielded one band (Fig. 6B).
Cold uPA wt oligonucleotide was able to compete for proteins
binding to the AP-1 site but was a little less efficient than
self-competition with cold AP-1 oligonucleotide. Mutation of
the AP-1 half of the uPA element (M8) abolished this compe-
tition, whereas mutation of the PEA3 half (M5) did not. Thus,
the octameric site in the uPA PEA3/AP-1 element (TGAG
GTCA) can bind some of the same factors which bind to a
conventional AP-1 site (TGAGTCA).
Treatment of BMM with CSF-1 or PMA increased the levels
of proteins binding to the AP-1 oligonucleotide (Fig. 6C). With
CSF-1 treatment, levels were highest at 1 h and subsequently
declined. However, CSF-1 and PMA did not synergize to in-
crease AP-1 binding activity. In fact, CSF-1 pretreatment pre-
vented induction of AP-1 binding activity by PMA. The same
pattern of inductions was found with labelled uPA wt oligonu-
cleotide, although the degree of induction was less pronounced
(result not shown). The low level of protein binding in extracts
from cells treated with CSF-1 and PMA together indicates that
uPA promoter activity does not correlate directly with the
induction of AP-1 binding activity.
DNA binding of Ets-1 and Ets-2 is known to be impeded by
a repressive domain under the conditions of EMSA (67). High-
affinity binding may require either posttranslational modifica-
tion or protein-protein interaction to relieve this repressive
FIG. 5. fms response of uPA promoter-CAT constructs transfected into NIH
3T3 cells. (A) NIH 3T3 cells were transiently transfected by calcium phosphate
coprecipitation with 3 mg of uPA-CAT reporter construct in the presence (1v-
fms) or absence (2) of 2.5 mg of the v-fms expression plasmid pSMFeSV (62).
(B) NIH 3T3/c-fms cells were transfected with 3 mg of uPA promoter-CAT
reporter constructs. After the precipitate was removed, the cells were either
grown in the presence of 104 U of CSF-1 per ml for 48 h and restimulated with
CSF-1 at 2 h before harvest (1CSF-1) or grown in the absence of CSF-1 (2).
CAT assays were done with equivalent amounts of protein as determined by
protein concentration. A plasmid expressing a secreted form of human placental
alkaline phosphatase was used as an internal control for transfection efficiency.
Thin-layer chromatography plates were autoradiographed and then analyzed
with a Betascope 603 blot analyzer (Betagen, Waltham, Mass.). Error bars in
both panels show the standard deviations of results from three separate exper-
iments.
FIG. 6. (A) EMSA of proteins binding to the uPA PEA3/AP-1 element and
mutated oligonucleotides. Nuclear extract was prepared from BMM starved of
CSF-1 for 16 h and then treated with 104 U of CSF-1 per ml for 3 h. Nuclear
protein (4.5 mg) was incubated with four different oligonucleotide probes la-
belled to achieve the same specific activity. Binding reactions were run on a 5%
acrylamide gel. Lane wt probe, no protein extract. Arrows indicate protein-DNA
complexes. (B) Competition for proteins binding to a labelled AP-1 oligonucle-
otide. AP-1 oligonucleotide was mixed with the indicated fold molar excess of
cold competitor before the addition of 1 mg of nuclear protein. Nuclear extract
was made from BMM grown in the presence of CSF-1. Binding reactions were
run on a 6% polyacrylamide gel. Free probe has been run off the bottom of the
gel. Lane no comp., no competing cold oligonucleotide. (C) Effect of treatment
of BMM with CSF-1 and PMA on AP-1 binding. BMM were either starved of
CSF-1 overnight (2CSF-1 O/N) and subsequently treated with CSF-1 for 1 or 3
h or with PMA for 1 h or left with continued CSF-1 stimulation (1CSF-1 O/N)
and subsequently treated with PMA for 1 h (1CSF-1 O/N 1PMA 1hr). Nuclear
protein (1 mg) was incubated with labelled AP-1 oligonucleotide before being
run on a 5% polyacrylamide gel. Oligonucleotides used were as follows: AP-1,
59CGCTTGATGAGTCAGCCGGAA39 (Promega); uPA wt, 59GGCCAGGAG
GAAATGAGGTCATCTTGCT39 (uPA PEA3/AP-1); uPA M5, 59GGCCAG
GAGGAAATGAGGAGATCTTGCT39 (AP-1 mutant); uPA M7, 59GGCCAG
TACCAAATGAGGTCATCTTGCT39 (PEA3 mutant); uPA M8, 59GGCCAG
GACCAAATGAGGTCATCTTGCT39 (PEA3 mutant); and uPA CRE, 59GA
AATGAGGTCATCTTGCT39 (AP-1 half-site).
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effect. Perhaps because of this problem and the lack of good
supershifting antibodies specific for Ets-2, to our knowledge
native Ets-2 binding activity in nuclear extracts has not been
clearly identified. Even using a consensus sequence deter-
mined for binding of recombinant Ets-2 DNA binding domain
(44), we could not detect a PMA- or CSF-1-inducible protein
in macrophages (result not shown), although ets-2 mRNA is
clearly induced (Fig. 1). To examine whether Ets-2 can bind
the uPA PEA3/AP-1 element, the DNA binding domain alone
was expressed as a GST fusion protein. Figure 7A shows that
the Ets-2 DNA binding domain binds the uPA wt oligonucle-
otide and can be competed for by the AP-1 mutant (uPA M5)
and an Ets-2 consensus oligonucleotide but not by the PEA3
mutant (uPA M8). On the basis of competition with increasing
concentrations of cold oligonucleotides, the uPA wt sequence
was evidently a much lower-affinity site for Ets-2 binding than
the Ets-2 consensus sequence (Fig. 7B).
DISCUSSION
A PEA3/AP-1 element was first identified in the polyoma-
virus enhancer. It mediated responses to serum, PMA, and the
v-src, Ha-ras, v-mos, v-raf, and polyomavirus middle-T-antigen
oncogenes (80) and has been termed a tetradecanoyl phorbol
acetate- and oncogene-responsive unit (28). Similar elements
have been found in other genes such as collagenase (28), trans-
forming growth factor b (50, 54), the NVL3 retrotransposon
(54), keratin 18 (51), uPA (56), and the macrophage scavenger
receptor (82) (Fig. 8). These elements have all been charac-
terized as ras-responsive elements. Although Rørth et al. (56)
mention that ras transformation of keratinocytes did not acti-
vate the uPA PEA3/AP-1 element, the element responded
strongly to activated ras in NIH 3T3 cells (16) and RAW264
macrophages (25). The collagenase and keratin 18 PEA3 and
AP-1 elements are more widely spaced (Fig. 8), but it is inter-
esting that the insertion of 10 bp in both cases corresponds to
one turn of the DNA helix and may give a similar orientation
of binding factors.
As noted in the introduction, the uPA PEA3/AP-1 site at
22430 in the mouse promoter mediates induction by signals
such as epidermal growth factor, PMA, and basic fibroblast
growth factor. In this work we have found that the uPA PEA3/
AP-1 element is involved in the transcriptional response to
CSF-1 in NIH 3T3/c-fms. Both halves of the element were
required for efficient activation of transcription by either v-fms
or c-fms with CSF-1 (Fig. 5). This may reflect the fact that the
PEA3 and AP-1 halves are comparatively weak binding sites
for Ets and AP-1 proteins (Fig. 6 and 7). Induction of uPA
mRNA by CSF-1 was prevented by both a dominant negative
Ets protein (Fig. 4) and the catalytic domain of GAP (16). uPA
induction by CSF-1 in this cell line therefore appears to involve
ras signalling and activation of Ets transcription factors. This
makes uPA regulation similar to that of both the NVL3 ret-
rotransposon and c-myc (6, 7, 39, 61). Work on the induction
of the NVL3 retrotransposon by CSF-1 in NIH 3T3/c-fms iden-
tified a PEA3/AP-1-like element mediating the CSF-1 re-
sponse (7, 54). This element had been previously identified as
a ras-responsive element (49). Another CSF-1-inducible gene,
the macrophage scavenger receptor gene, contains a similar
ras- and PMA-responsive element, although this element has
not yet been directly shown to be activated by CSF-1 (82).
Comparison of the NVL3, uPA, and scavenger receptor PEA3/
AP-1 elements (Fig. 8) shows similar spacings of elements but
a number of sequence differences. Wu et al. (82) found that
Ets-2, but not Ets-1, was able to transactivate the scavenger
receptor element and to cooperate with c-Jun. This differs
from results for the uPA element in RAW264 cells, in which
Ets-2 and Ets-1 have similar activities.
FIG. 7. Binding of the Ets-2 DNA binding domain to the uPA PEA3/AP-1
element. (A) Purified bacterially expressed GST-Ets-2 fusion protein and control
GST protein were incubated with labelled uPA wt oligonucleotide. When cold
competitors were used, they were preincubated with the protein for 15 min
before the addition of the labelled probe. Samples were loaded onto a 6%
polyacrylamide gel 15 min after the addition of labelled probe. (B) Competition
for GST-Ets-2 fusion protein binding to the labelled uPA wt oligonucleotide by
either cold uPA wt or Ets-2 consensus oligonucleotides. Labelled probe and the
indicated molar excesses of cold competitor were mixed together before the
addition of protein. After 30 min, samples were loaded onto a 6% polyacryl-
amide gel. The Ets-2 consensus oligonucleotide (59CTAGGACCGGAAGTGG
GAGT39) is based on sequences established by R. Maki (La Jolla Cancer Re-
search Foundation), using recombinant Ets-2 DNA binding domain and random
oligonucleotides. Other oligonucleotides used are as indicated in the legend to
Fig. 6.
FIG. 8. Functional PEA3/AP-1 elements identified in a number of genes. Ets
core binding sequences (GGAA or GGAT) (78) are underscored, and AP-1-like
sequences are indicated by dashed underlining.
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Introduction of a mutation at Tyr-809 in the CSF-1R pre-
vents induction of c-myc, the NVL3 gene, and the mitogenic
response in NIH 3T3/c-fms treated with CSF-1 (39, 60, 64).
These effects are mimicked by the expression of dominant
negative Ets-2 (39). CSF-1-induced mitogenesis can be re-
stored to cells with the Tyr-809 mutation by the expression of
ets-1, ets-2, or c-myc (39, 60, 61), and induction of c-myc ap-
pears to involve Ets factors (61). This implicates an Ets factor
with binding specificity and activity similar to those of Ets-1
and Ets-2 in the CSF-1 signalling pathway in these cells. The
identification of the NVL3 and uPA PEA3/AP-1 sequences as
promoter targets of CSF-1 is an important step towards finding
the specific transcription factors involved in signalling.
The 39 half of the uPA PEA3/AP-1 site is octameric and
more closely resembles a CRE (TGACGTCA) than it does the
consensus AP-1 site (TGA[C/G]TCA). The distinction be-
tween CRE and AP-1 sites has become blurred by the findings
that AP-1 factors can dimerize with the CRE-binding factors
(CREB/ATF family) (29) and that AP-1 factors themselves can
also bind to octameric sequences (1, 65). The wide range of Ets
family proteins and AP-1 and CREB/ATF proteins makes the
determination of which factors bind these elements a chal-
lenge. The octameric site in uPA is not responsive to cAMP
and functions similarly to an AP-1 site (40). In extracts from
pig kidney epithelial cells, c-Jun has been found to bind the pig
uPA PEA3/AP-1 element (41). In another study, a c-Jun/ATF2
heterodimer has been shown to bind the AP-1 half of the uPA
PEA3/AP-1 element (19). Macrophage AP-1-binding factors
will also clearly bind to the octameric uPA AP-1 sequence (Fig.
6), although with slightly lower affinity than to a conventional
AP-1 site. When either a labelled AP-1 oligonucleotide (Fig.
6C) or the uPA PEA3/AP-1 element (25) was used, treatment
with CSF-1 or PMA increased levels of AP-1 factor binding.
However, CSF-1 pretreatment prevented induction of AP-1
factors by PMA. Hence, the synergy seen in induction of uPA
mRNA (Fig. 1) is not due to synergistic induction of general
AP-1 binding activity.
The effect of PEA3 site mutation in transient-expression
analysis (Fig. 3) showed that this element was functionally
important. Despite this, with EMSA we were unable to detect
any strong binding of macrophage nuclear factors to the PEA3
half of the uPA element. The two major detectable bands were
both accounted for by proteins binding to the AP-1 site (Fig.
6). Conditions used in making nuclear protein extracts or in
EMSA may be inadequate for detecting factors binding to the
PEA3 site. In EMSA with extract from pig kidney LLC-PK1
cells, only one complex was observed; this result was explain-
able by c-Jun binding to the AP-1 half of the pig uPA PEA3/
AP-1 element (41). However, in vivo footprinting showed the
uPA PEA3 site to be constitutively occupied regardless of
enhancer activity (46). Owen and Ostrowski (50) found a 120-
kDa protein in NIH 3T3 which can bind to the NVL3 PEA3
site and does not correspond to known Ets factors. In studies
of the scavenger receptor element, large amounts of protein
were required before evidence of binding to the PEA3 half of
the element was observed (82).
Mutation of the PEA3 site reduced the high level of trans-
activation by Ets-2 (Fig. 3C), suggesting that Ets-2 acts through
this site. Bacterially expressed Ets-2 DNA binding domain was
clearly capable of binding to this element, but it is a lower-
affinity site than the consensus Ets-2 binding site (Fig. 7). It is
impossible to determine what represents sufficient affinity to be
of biological relevance, especially as the uPA site is a com-
pound element and cooperative binding could increase the
effective affinity. The evidence that Ets-2 can transactivate
through this site, is capable of binding to it, and is induced by
CSF-1 makes it a good candidate for a normal regulator of
uPA in vivo.
The macrophage cell line RAW264 can be readily trans-
fected and responds to CSF-1 with a three- to sixfold induction
of uPA mRNA (Fig. 1) (71, 72). In contrast to that of BMM,
this induction did not seem to be mediated at the transcrip-
tional level (Fig. 2). The rate of transcription of uPA in
RAW264 cells was low compared with that in CSF-1-stimu-
lated BMM (Fig. 2), leading us to propose that in RAW264
cells there is a deficiency in the CSF-1 signal transduction
pathway leading to uPA gene transcription. Recent results
comparing protein tyrosine phosphorylation levels in RAW264
cells and BMM show similar levels of induction of phosphor-
ylation by CSF-1 in the two cell types, including phosphoryla-
tion of mitogen-activated protein kinases (25). Thus, there
appears to be no fundamental defect in CSF-1R function in
RAW264 cells. RAW264 cells are transformed by Abelson
leukemia virus, which presumably encodes an active v-abl ty-
rosine kinase. This tyrosine kinase activity may lead to the
down-regulation of a factor in the CSF-1 signalling pathway.
A simple hypothesis to account for the poor level of induc-
tion of uPA by CSF-1 in RAW264 cells is that uPA transcrip-
tion is regulated by Ets-2 and CSF-1 fails to induce ets-2
mRNA efficiently in the cell line (Fig. 1). If Ets-2 is involved in
the normal regulation of the uPA gene, then the synergistic
induction of uPA mRNA by CSF-1 and PMA could be at least
partly accounted for by synergistic effects of the two agents on
ets-2 mRNA levels (Fig. 1).
An alternative interpretation is that ets-2 and uPA are reg-
ulated in parallel, via the activation of another Ets protein.
However, the time course of ets-2 mRNA induction and decay
is quite different from that for uPA (25). The ets-2 gene pro-
moter itself contains an Ets factor binding site involved in
expression of the gene, and protein binding to an adjacent
promoter element was competed for, although not efficiently,
by an AP-1 oligonucleotide (45). Whether this element func-
tions in the same way as the uPA element remains to be
established. Other Ets factors expressed in macrophages in-
clude PU.1 (57), Elf-1 (32), and Fli-1 (36). Neither PU.1 nor
Elf-1 was able to effectively transactivate the uPA promoter
(Fig. 3D), although the uPA PEA3 element is similar to a
published Elf-1 binding site (AGGAGGAAAA [74]) and an
Elf-1 binding site is closely associated with an AP-1 site in the
human interleukin-3 gene (27).
Although analysis of the CSF-1 response in transfected
RAW264 cells was not possible, the PEA3/AP-1 element was
identified as a PMA-responsive element in this cell line (Fig.
3B). The same element mediated a response to PMA in kera-
tinocytes (56) and in the pig kidney epithelial cell line LLC-
PK1 (41). In HepG2 hepatoma cells, the cooperation between
the PEA3/AP-1 site and a downstream AP-1 site was necessary
for induction by PMA (47).
Although both PMA and CSF-1 are able to activate the
PEA3/AP-1 element, the evidence does not support the hy-
pothesis that the pathways of activation are coincident. Both
the synergy between CSF-1 and PMA in induction of uPA
mRNA in BMM (Fig. 1) and the differential response of
RAW264 cells to CSF-1 and PMA in transient transfections
suggest that CSF-1 and PMA induce uPA by distinct mecha-
nisms. PMA does not mimic the action of CSF-1. The two
agonists may activate separate pathways or may have synergis-
tic effects on the one signalling pathway. Although some evi-
dence that CSF-1 activates PKC has been presented (34, 66), a
recent study suggests that PKC activation is not significant, at
least not in early signalling by CSF-1 (35). Like CSF-1 (2),
PMA and PKC can activate Raf-1 (38). It will be interesting to
3438 STACEY ET AL. MOL. CELL. BIOL.
ascertain whether PMA can increase Raf-1 activation when
added to CSF-1-treated cells.
PMA is frequently used in promoter studies without indica-
tion of its physiological relevance. There may be natural stim-
uli which act through PKC and strongly enhance the induction
of uPA by CSF-1. Transforming growth factor b induces uPA
in RAW264 cells and may act through a PKC-dependent
mechanism (24). It is also possible that PMA provides a com-
bination of stimuli to cells which does not resemble the action
of any physiological molecule.
In this work we have provided evidence that the CSF-1
response of the uPA gene is distinct from the response to
PMA, is mediated through a PEA3/AP-1 element, and re-
quires activation of an Ets transcription factor, possibly Ets-2.
Earlier evidence pointed to bifurcating signalling pathways
from the CSF-1 receptor, one through ras, raf, Ets, and myc
factors and another leading to induction of fos and jun proteins
(7, 9, 39, 60). Although ras is generally considered an activator
of Raf-1, recent work showed that ras and Raf-1 were activated
independently by CSF-1 in the macrophage cell line BAC1.2F5
(10) and are therefore likely to be part of cooperating but
separate pathways. Since expression of v-raf in BAC1.2F5 mac-
rophages leads to constitutive expression of ets-2 mRNA (9),
induction of ets-2 by CSF-1 may be due to activation of a
pathway involving Raf-1. We have found that coexpressed
Ets-2 and activated ras in RAW264 cells synergistically in-
crease uPA promoter activity (25). This is consistent with a
model in which a Raf-1-activated pathway induces Ets-2 ex-
pression and ras either activates Ets-2 or induces cooperating
factors.
Many studies of the CSF-1 signal transduction pathway have
been performed with fibroblasts expressing the CSF-1R. This is
partly due to the difficulties of transfection and manipulation
of macrophages. In this study we have used NIH 3T3 cells
expressing c-fms, as the transfectable macrophage cell lines
available to us did not respond adequately to CSF-1 with tran-
scriptional activation of the uPA gene. Differences in CSF-1
signalling between fibroblasts and macrophages have been de-
tected (43), and the challenge remains to confirm with macro-
phages the results of numerous studies performed with fibro-
blasts.
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